Tetra Pharm Technologies concludes preclinical testing of TPT0301 in preparation of First-in-Human clinical trials

Following convincing results from a recent In-Vitro study, the Danish biotech company, Tetra Pharm Technologies, announces successful In-Vivo study results of its candidate compound, TPT0301.